EP. 1: AEs from Novel Hormone Therapy in Nonmetastatic Castrate Resistant Prostate Cancer
In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.
EP. 2: AEs from PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer
EP. 3: AEs from Immunotherapy monotherapy for BCG-Unresponsive NMIBC
Study shows persistent bone protective effect of menopausal hormone therapy
Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC
Aquablation procedures for prostate cancer completed at ambulatory surgery center
FDA grants priority review to expanded indication of flibanserin in HSDD
